Antimicrobials
Daptomycin

Daptomycin

Restricted

Low
N/A

Spectrum of Activity

General Information

HEALTH CANADA APPROVED

  • Treatment of complicated skin and skin structure infections caused by the following aerobic Gram-positive bacteria: S. aureus (including methicillin-resistant strains), S. pyogenes and S. agalactiae
  • Treatment of S. aureus bacteremia including infection with right-sided S. aureus infective endocarditis (native valve)

Note: HEALTH PEI has restricted the use of DAPTOmycin

  • To treat moderate to severe suspected MRSA non-respiratory infections in patients who are truly allergic to vancomycin OR
  • At the opinion of the Medical Microbiologist or an Infectious Disease consultant

Not indicated for use in pneumonia since its activity is inhibited in the presence of pulmonary surfactant

HMG-CoA reductase inhibitors: increased risk of developing myopathy. Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to DAPTOmycin

RECOMMENDED

  • Signs and symptoms of myopathy (muscle pain or weakness, particularly of the distal extremities)
  • Baseline and weekly CK levels during therapy (more frequent monitoring if history of current or prior statin therapy and/or renal impairment)
  • Signs of peripheral neuropathy

HEALTH PEI has restricted the use of DAPTOmycin:

  • To treat moderate to severe suspected MRSA non-respiratory infections in patients who are truly allergic to vancomycin OR
  • At the opinion of the Medical Microbiologist or an Infectious Disease consultant

Antimicrobial class: Cyclic Lipopeptide Antibiotic

Pregnancy category: B

Average serum half life: 9 hours

Urine penetration: Therapeutic

Lung penetration: Poor

CSF penetration: Poor

pH: 6.8 (Cubicin RF)